 |
|
Improving Human and Animal Health With Protein Engineering.
|
|
|
Trophogen Inc. Funding Summary
Trophogen Inc. is a biotech company that, in addition to receiving generous initial seed and series A venture capital funding from Toucan Capital,
has received numerous highly competitive SBIR grants, as well as federal stimulus grant funding. Trophogen’s grant application success is captured in
the following tables.
|
NIH/SBIR Grant Awards
| GRANT TITLE |
DATE OF AWARD |
AWARD AMOUNT |
NOVEL LONG ACTING RHTSH SUPERAGONIST ANALOGS FOR IMPROVED DIAGNOSTIC IMAGING,
THYROGLOBULIN STIMULATION AND THERAPY OF THYROID CANCER
PHASE 1/2 (Drs. Weintraub & Szkudlinski)
| 09/11/2018
| $1,842,610
|
|
NOVEL RECOMBINANT HIGH-AFFINITY, LONG- AND DUAL-ACTING EQUINE CHORIONIC
GONADOTROPIN ANALOGS FOR IMPROVED AND MORE ETHICAL REPRODUCTION
IN PIGS AND CATTLE.
PHASE 1/2 (Drs. Weintraub & Szkudlinski)
| 09/18/2017
| $2,188,368
|
|
NOVEL HIGH AFFINITY VEGF ANALOGS FOR
TARGETED IMAGING OF THYROID CANCER
PHASE 1/2 (Drs. Weintraub & Szkudlinski)
| 11/2013
| $283,958
|
|
NOVEL LONG ACTING BOVINE
FSH SUPERAGONIST
PHASE 1 (Drs. Weintraub & Szkudlinski)
| 9/11/2012
| $150,000
|
|
DEVELOPMENT OF SUPERACTIVE ANALOGS
OF FSH FOR HUMAN INFERTILITY
PHASE 2 (Dr. Weintraub)
| 9/12/2011
| $1,944,124 |
|
RECOMBINANT HUMAN TSH SUPERAGONISTS
FOR IMAGING OF THYROID CANCER
PHASE 2 (Dr. Weintraub)
| 7/23/2010 |
$1,739,909 |
|
DEVELOPMENT OF SUPERAGONIST
ANALOGS OF RECOMBINANT HUMAN TSH FOR
IMAGING AND THERAPY OF THYROID CANCER
PHASE 2 (Dr. Weintraub)
| 9/1/2008
| $1,774,735 |
|
RECOMBINANT HUMAN TSH SUPERAGONISTS
FOR IMAGING OF THYROID CANCER
PHASE 1 (Dr. Weintraub)
|
9/21/2006
| $478,846
|
|
DEVELOPMENT OF SUPERAGONIST ANALOGS
OF RECOMBINANT HUMAN TSH
PHASE 1 (Dr. Weintraub) |
6/12/2006
| $101,500
|
|
DEVELOPMENT OF SUPERACTIVE ANALOGS
OF FSH
PHASE 2 (Dr. Weintraub) |
2/28/2006
| $1,217,268
|
|
DEVELOPMENT OF NOVEL VEGF ANALOGS
PHASE 1 (Dr. Szkudlinski)
| 8/30/2005
| $108,000 |
|
DEVELOPMENT OF SUPERACTIVE
ANALOGS OF LH & FSH
PHASE 1 (Dr. Weintraub)
|
6/1/2004 |
$100,000
|
Competitive Federal Stimulus Grant Awards
Type of grants: Qualifying Theraputic Discovery Grant
| GRANT TITLE |
DATE OF AWARD |
AWARD |
|
| DEVELOPMENT OF TSH SUPERAGONIST ANALOGS FOR DIAGNOSIS AND TREATMENT OF THYROID CANCER |
10/29/2010 | $244.479 |
|
| DEVELOPMENT OF FSH SUPERAGONIST ANALOGS FOR INFERTILITY AND OVARIAN CANCER |
10/29/2010 | $203.453 |
|